Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RM803
- Development stage
- Preclinical
- Lead developer
- Guangzhou Reforgene Medicine
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies
- Administration
- Intravenous
01
Overview
RM803 is an investigational in vivo gene-editing therapeutic candidate currently in the preclinical stage of development. It is being developed by Guangzhou Reforgene Medicine, a biotechnology company specializing in CRISPR-based genetic medicines. The program is designed to address undisclosed indications within the cardiovascular and hepatic therapeutic areas. As an in vivo gene-editing asset, RM803 likely utilizes a delivery system, such as lipid nanoparticles (LNPs) or viral vectors, to transport gene-editing machinery (e.g., CRISPR/Cas systems) directly to target tissues to achieve therapeutic modification of specific genetic sequences.
Beyond the preview
Go deeper on RM803.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RM803.